Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of TJ011133 Administered Alone or in Combination With Pembrolizumab or Rituximab in Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma

NCT03934814 is registered in ClinicalTrials.gov with I-Mab Biopharma US Limited as lead sponsor.

NCT NCT03934814
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03934814 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of TJ011133 Administered Alone or in Combination With Pembrolizumab or Rituximab in Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma
Lead sponsor
I-Mab Biopharma US Limited
Phase
Phase 1
Overall status
Completed
Start date
April 16, 2019
Completion date
January 10, 2023
Enrollment
98 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, solid tumor